GlaxoSmithKline braced investors for the likely launch of a cheap copycat of its blockbuster respiratory drug Advair in the U.S., saying such competition would scuttle any profit growth in 2017.
from WSJ.com: US Business http://ift.tt/2kHT5ve
via IFTTT
No comments:
Post a Comment